• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?

作者信息

Casillo Gian Marco, Mansour Adel Abo, Raucci Federica, Saviano Anella, Mascolo Nicola, Iqbal Asif Jilani, Maione Francesco

机构信息

ImmunoPharmaLab, Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Via Domenico Montesano 49, 80131, Naples, Italy.

Institute of Cardiovascular Sciences (ICVS), College of Medical and Dental Sciences, University of Birmingham, Birmingham, B15 2TT, UK; Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Guraiger, Abha, 62529, Saudi Arabia.

出版信息

Pharmacol Res. 2020 Jun;156:104791. doi: 10.1016/j.phrs.2020.104791. Epub 2020 Apr 14.

DOI:10.1016/j.phrs.2020.104791
PMID:32302707
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7194796/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc43/7194796/4dbbf9f7e9e8/ga1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc43/7194796/4dbbf9f7e9e8/ga1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cc43/7194796/4dbbf9f7e9e8/ga1_lrg.jpg

相似文献

1
Could IL-17 represent a new therapeutic target for the treatment and/or management of COVID-19-related respiratory syndrome?白细胞介素-17能否成为治疗和/或管理新型冠状病毒肺炎相关呼吸综合征的新治疗靶点？
Pharmacol Res. 2020 Jun;156:104791. doi: 10.1016/j.phrs.2020.104791. Epub 2020 Apr 14.
2
[Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].[严重急性呼吸综合征冠状病毒2（SARS-CoV-2）：我们应该针对病毒、细胞还是疾病？]
Virologie (Montrouge). 2020 Jun 1;24(3):135-141. doi: 10.1684/vir.2020.0843.
3
Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome.2019冠状病毒病治疗的紧急途径：针对下游炎症以预防灾难性综合征。
Joint Bone Spine. 2020 May;87(3):191-193. doi: 10.1016/j.jbspin.2020.03.011.
4
Coronavirus disease 2019 (COVID-19) and anti-rheumatic drugs.2019年冠状病毒病（COVID-19）与抗风湿药物
Rheumatol Int. 2020 May;40(5):825-826. doi: 10.1007/s00296-020-04570-z. Epub 2020 Mar 30.
5
Immunomodulation in COVID-19.新型冠状病毒肺炎中的免疫调节
Lancet Respir Med. 2020 Jun;8(6):544-546. doi: 10.1016/S2213-2600(20)30226-5. Epub 2020 May 4.
6
Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019.严重急性呼吸综合征冠状病毒2对干扰素表达的弱诱导作用支持了干扰素λ治疗早期2019冠状病毒病的临床试验。
Clin Infect Dis. 2020 Sep 12;71(6):1410-1412. doi: 10.1093/cid/ciaa453.
7
Audio Interview: Tocilizumab and Covid-19.音频访谈：托珠单抗与新冠病毒
N Engl J Med. 2020 Oct 22;383(17):e114. doi: 10.1056/NEJMe2032051.
8
Potential role of anti-interleukin-17 in COVID-19 treatment.
Dermatol Ther. 2020 Jul;33(4):e13715. doi: 10.1111/dth.13715. Epub 2020 Jun 20.
9
SARS-CoV-2: a time for clear and immediate action.严重急性呼吸综合征冠状病毒2：是采取明确且立即行动的时候了。
Lancet Infect Dis. 2020 May;20(5):531-532. doi: 10.1016/S1473-3099(20)30250-4. Epub 2020 Mar 31.
10
Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm.熊去氧胆酸作为一种缓解和/或预防新冠病毒相关细胞因子风暴的候选治疗药物。
Med Hypotheses. 2020 Oct;143:109897. doi: 10.1016/j.mehy.2020.109897. Epub 2020 May 30.

引用本文的文献

1
Bridging worlds: a narrative review of IL-17 at the crossroads of inflammation and thrombosis.跨越界限：关于白细胞介素-17在炎症与血栓形成交叉点的叙述性综述
Inflamm Res. 2025 Sep 4;74(1):118. doi: 10.1007/s00011-025-02081-w.
2
Co-infection with and COVID-19 with lethal outcome. First clinical case from Bulgaria.与[具体病原体]共同感染新冠病毒并导致死亡。保加利亚的首例临床病例。
Oxf Med Case Reports. 2024 Apr 25;2024(4):omae048. doi: 10.1093/omcr/omae048. eCollection 2024 Apr.
3
The striking mimics between COVID-19 and malaria: A review.

本文引用的文献

1
3CL inhibitors as a potential therapeutic option for COVID-19: Available evidence and ongoing clinical trials.3CL抑制剂作为COVID-19的一种潜在治疗选择：现有证据及正在进行的临床试验
Pharmacol Res. 2020 Jun;156:104779. doi: 10.1016/j.phrs.2020.104779. Epub 2020 Apr 2.
2
Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2).连花清瘟对新型冠状病毒（SARS-CoV-2）具有抗病毒和抗炎作用。
Pharmacol Res. 2020 Jun;156:104761. doi: 10.1016/j.phrs.2020.104761. Epub 2020 Mar 20.
3
TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.
COVID-19 与疟疾的惊人相似之处：综述。
Front Immunol. 2022 Aug 23;13:957913. doi: 10.3389/fimmu.2022.957913. eCollection 2022.
4
The common regulatory pathway of COVID-19 and multiple inflammatory diseases and the molecular mechanism of cepharanthine in the treatment of COVID-19.新型冠状病毒肺炎与多种炎症性疾病的共同调控途径及千金藤素治疗新型冠状病毒肺炎的分子机制
Front Pharmacol. 2022 Jul 22;13:960267. doi: 10.3389/fphar.2022.960267. eCollection 2022.
5
Investigating the effect of macro-scale estimators on worldwide COVID-19 occurrence and mortality through regression analysis using online country-based data sources.通过使用基于在线国家数据源的回归分析，研究宏观尺度估计值对全球 COVID-19 发病和死亡的影响。
BMJ Open. 2022 Feb 14;12(2):e055562. doi: 10.1136/bmjopen-2021-055562.
6
An updated overview of recent advances, challenges, and clinical considerations of IL-6 signaling blockade in severe coronavirus disease 2019 (COVID-19).白细胞介素 6 信号阻断在严重 2019 年冠状病毒病（COVID-19）中的最新进展、挑战和临床考虑的更新概述。
Int Immunopharmacol. 2022 Apr;105:108536. doi: 10.1016/j.intimp.2022.108536. Epub 2022 Jan 11.
7
COVID-19 and Rheumatoid Arthritis Crosstalk: Emerging Association, Therapeutic Options and Challenges.COVID-19 与类风湿关节炎的相互作用：新兴关联、治疗选择与挑战。
Cells. 2021 Nov 24;10(12):3291. doi: 10.3390/cells10123291.
8
Biology and Pathogenesis of SARS-CoV-2: Understandings for Therapeutic Developments against COVID-19.严重急性呼吸综合征冠状病毒2的生物学与发病机制：对COVID-19治疗进展的认识
Pathogens. 2021 Sep 19;10(9):1218. doi: 10.3390/pathogens10091218.
9
Evaluating the Role of the Interleukin-23/17 Axis in Critically Ill COVID-19 Patients.评估白细胞介素-23/17轴在危重症新型冠状病毒肺炎患者中的作用
J Pers Med. 2021 Sep 7;11(9):891. doi: 10.3390/jpm11090891.
10
Genome-scale metabolic modelling of SARS-CoV-2 in cancer cells reveals an increased shift to glycolytic energy production.对癌细胞中的 SARS-CoV-2 进行基因组规模代谢建模，揭示了向糖酵解能量产生的增加转变。
FEBS Lett. 2021 Sep;595(18):2350-2365. doi: 10.1002/1873-3468.14180. Epub 2021 Sep 5.
COVID-19 细胞因子风暴中的 TH17 反应：JAK2 抑制剂 Fedratinib 的一个新靶点。
J Microbiol Immunol Infect. 2020 Jun;53(3):368-370. doi: 10.1016/j.jmii.2020.03.005. Epub 2020 Mar 11.
4
Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19.严重 COVID-19 患者临床实验室数据测定的诊断效用。
J Med Virol. 2020 Jul;92(7):791-796. doi: 10.1002/jmv.25770. Epub 2020 Apr 10.
5
Transmission routes of 2019-nCoV and controls in dental practice.2019-nCoV 的传播途径与口腔诊疗中的感染控制
Int J Oral Sci. 2020 Mar 3;12(1):9. doi: 10.1038/s41368-020-0075-9.
6
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.中国武汉 99 例 2019 年新型冠状病毒肺炎患者的流行病学和临床特征：描述性研究。
Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30.
7
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
8
From IL-15 to IL-33: the never-ending list of new players in inflammation. Is it time to forget the humble aspirin and move ahead?从白介素 15 到白介素 33：炎症领域中不断涌现的新角色。是时候摒弃阿司匹林，转而前进了吗？
Biochem Pharmacol. 2010 Feb 15;79(4):525-34. doi: 10.1016/j.bcp.2009.09.015.
9
Interactions between respiratory epithelial cells and cytokines: relationships to lung inflammation.呼吸道上皮细胞与细胞因子之间的相互作用：与肺部炎症的关系。
Ann N Y Acad Sci. 1994 May 28;725:128-45. doi: 10.1111/j.1749-6632.1994.tb00275.x.